Episode 16: ESMO 2024 Commentary: Kidney Cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d2/9a/09/d29a09bb-6bb4-d3b6-1911-aad1979f4b90/mza_8029225495197491321.jpg/600x600bb.jpg

The View on GU | with Lalani and Wallis

Dr. Aly-Khan Lalani & Dr. Christopher Wallis

36 episodes

1 day ago

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.

Medicine

Health & Fitness

RSS

All content for The View on GU | with Lalani and Wallis is the property of Dr. Aly-Khan Lalani & Dr. Christopher Wallis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40427888/41d07e9c28fc00dc.jpeg

Episode 16: ESMO 2024 Commentary: Kidney Cancer

The View on GU | with Lalani and Wallis

21 minutes 45 seconds

1 year ago

Episode 16: ESMO 2024 Commentary: Kidney Cancer

Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don’t) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.